Life's essential 8 and mortality in US adults with metabolic dysfunction-associated steatotic liver disease

被引:0
|
作者
Zhang, Yingying [1 ]
Wang, Pingping [2 ]
Tu, Fan [1 ]
Kang, Hao [3 ]
Fu, Chengfeng [4 ]
机构
[1] Jiangnan Univ, Affiliated Wuxi Hosp 5, Med Lab Ctr, 1215 Guangrui Rd, Wuxi 214005, Jiangsu, Peoples R China
[2] Yangzhou Univ, Taizhou Peoples Hosp 2, Dept Clin Lab, Taizhou, Jiangsu, Peoples R China
[3] Jiangnan Univ, Affiliated Wuxi Hosp 5, Res Ctr Clin Med Sci, Wuxi, Jiangsu, Peoples R China
[4] Second Peoples Hosp Banan Dist, Resp & Crit Care Med, 18 Huaxi New Village,Huaxi St, Chongqing 400054, Peoples R China
关键词
MASLD; Life's essential 8; All-cause mortality; CVD mortality; National health and nutrition examination survey; AMERICAN HEART ASSOCIATIONS; CARDIOVASCULAR HEALTH; METAANALYSIS; OUTCOMES; METRICS; NHANES; RISK;
D O I
10.1186/s12889-024-20919-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to increased all-cause mortality due to metabolic dysfunctions like obesity, diabetes, and cardiovascular diseases. This study examines the association between Life's Essential 8 (LE8) scores and both all-cause and cardiovascular disease (CVD) mortality in MASLD participants. Methods Data from 5,916 MASLD participants in the NHANES (2005-2018) were analyzed. Associations between LE8 scores and all-cause and CVD mortality were assessed using Cox proportional hazards models, with follow-up until December 31, 2019. Dose-response relationships and survival differences were evaluated using Kaplan-Meier survival curves and Restricted Cubic Spline models. Results Over a median follow-up of 7.6 years, moderate and high LE8 scores were associated with 33% (HR: 0.67; 95% CI: 0.56-0.79) and 47% (HR: 0.53; 95% CI: 0.33-0.84) lower risk of all-cause mortality, respectively, compared to low scores. For CVD mortality, the adjusted HRs were 0.56 (95% CI: 0.41-0.78) and 0.35 (95% CI: 0.12-1.0). Higher LE8 scores were significantly associated with reduced cumulative incidence of all-cause and CVD mortality (log-rank P < 0.001). A 10-point increase in health behavior scores, particularly in diet, physical activity, and nicotine exposure, was linked to an 11% reduction in all-cause mortality risk and an 11% reduction in CVD mortality risk. Among health factors, only blood glucose showed a significant association with CVD mortality. Conclusion Higher LE8 scores in MASLD patients are associated with lower mortality risk, suggesting the potential value of promoting cardiovascular health in this population. Further research is needed to confirm these associations.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease
    Hu, Jingjing
    Du, Yuteng
    Zhou, Yidan
    Wang, Huiying
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [22] Cardiometabolic phenotype linked to fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease
    Dong, Rui
    Tian, Ting
    Luo, Zhenghan
    Chang, Dongchun
    Xue, Hong
    Qu, Sen
    Wang, Jia
    Shen, Chao
    Zhang, Ru
    Wang, Jie
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2025, 35 (03)
  • [23] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [24] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255
  • [25] Mechanobiology in Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity
    Rudolph, Emily L.
    Chin, LiKang
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 7134 - 7146
  • [26] Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Nendouvhada, Livhuwani P.
    Sibuyi, Nicole R. S.
    Fadaka, Adewale O.
    Meyer, Samantha
    Madiehe, Abram M.
    Meyer, Mervin
    Gabuza, Kwazikwakhe B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [27] Metabolic dysfunction-associated steatotic liver disease and gut microbiota
    Petryna, Vitalii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S285 - S285
  • [28] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 452 - 464
  • [29] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [30] Postbiotic supplementation for metabolic dysfunction-associated steatotic liver disease
    Savytska, Maryana
    Baka, Olena
    Manzhalii, Elina
    Kyriienko, Dmytro
    Falalyeyeva, Tetyana
    Zhayvoronok, Maksym
    Kovalchuk, Oleksandr
    Deresh, Nataliya
    Grygoriev, Fedir
    Kobyliak, Nazarii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S610 - S611